Viragen appoints Mount Sinai CEO Fred Hirt to its board of directors.MIAMI--(BUSINESS WIRE)--Jan. 13, 1997-- Company also names Charles F. Fistel, executive vice president, to board Viragen Inc. (NASDAQ/NMS:VRGN VRGN Virtual Reality Games Network ) Monday announced that Fred D. Hirt, president and chief executive officer of Mount Sinai Medical Center, Miami Beach, Fla., has been elected to its board of directors. Hirt has had a distinguished 20 year career as a senior executive in the healthcare industry, including serving as a consultant to several federal and local governmental healthcare agencies. He is also an accomplished lecturer, commentator and author on healthcare topics. Hirt stated: "I am delighted to work with a group of such outstanding individuals who are striving to find solutions to some of the nation's most devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. health problems. Their current dedicated study to treat HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome in hemophiliac he·mo·phil·i·ac n. A person who is affected with hemophilia. hemophiliac an animal affected with hemophilia. patients is laudable and I am proud to be part of such an important emerging company." Gerald Smith, Viragen's chairman and president, added: "We are honored to have Fred join the company's board. His wealth of knowledge, experience and contacts within the global healthcare and pharmaceutical industries makes him a valued addition to the company." The company also announced that Charles F. Fistel, its executive vice president, Corporate Development, has been elected to the company's board of directors. Fistel has served as a member of the company's Executive Committee since joining Viragen in June 1994. Smith stated, "Charles' efforts in managing the company's new business and strategic development programs have earned him this place on the board." Viragen Inc. is an emerging biopharmaceutical company engaged in the research, development, manufacture and clinical study of natural human interferons for the treatment of various viral diseases and immune disorders, including HIV/AIDS, hepatitis B & C and multiple sclerosis. The company's subsidiary, Viragen (Europe) Ltd. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on SmallCap:VERP VERP Variable Envelope Return Path (email server internal architecture component) VERP Voluntary Early Retirement Program VERP Ventricular Effective Refractory Period (cardiology) VERP Verification Plan ) is currently developing a manufacturing facility in Edinburgh, Scotland, for the production of Omniferon(tm), the company's second generation natural human alpha interferon product. CONTACT: Viragen Inc. Dennis W. Healey, CFO See Chief Financial Officer. 305/557-6000 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion